Ionis Pharmaceuticals Inc (Nasdaq: IONS) announced on Monday that the FDA has accepted its New Drug Application (NDA) for donidalorsen, an RNA-targeted therapy designed to prevent hereditary angioedema (HAE) attacks in patients aged 12 and older. The Prescription Drug User Fee Act (PDUFA) target decision date is set for 21 August 2025.
Assuming approval, donidalorsen would be the first RNA-targeted prophylactic treatment for HAE, and Ionis' second independent commercial launch. The FDA's decision follows positive results from the Phase 3 OASIS-HAE trial and ongoing Phase 2 and Phase 3 open-label studies, which demonstrated a 96% sustained reduction in HAE attack rates over three years.
Donidalorsen works by targeting prekallikrein (PKK), a key enzyme in the inflammatory pathway associated with HAE attacks. With Orphan Drug Designation granted by the FDA in 2023, Ionis and its partner Otsuka are preparing a Marketing Authorization Application for European regulatory submission.
Ionis, a leader in RNA-targeted medicine, has pioneered innovations across multiple therapeutic areas and currently markets five drugs, with a robust pipeline aimed at meeting high unmet needs in neurology, cardiology and other critical fields.
Correction - DeepHealth expands FDA clearance for SmartMammo Dx with GE HealthCare integration
DeepHealth expands FDA clearance for SmartMammo Dx with GE HealthCare integration
Formosa Pharmaceuticals licenses eye drops for Switzerland and Liechtenstein
Galderma reports Phase III data for nemolizumab in prurigo nodularis published in JAMA Dermatology
AOP Health's Rapiblyk approved by FDA for atrial fibrillation and atrial flutter
PTC Therapeutics to sell Priority Review Voucher for USD150m
Novartis' Kisqali approved in EU for broader population of high-risk early breast cancer patients
Merck reports positive Phase 3 ZENITH results for WINREVAIR in PAH treatment
Alnylam's sNDA for vutrisiran accepted by FDA; PDUFA date set for March 2025
GSK plc announces US FDA acceptance of review for Blenrep combinations in multiple myeloma
Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical announce progress in BH3120 clinical trial
Johnson & Johnson seeks FDA approval for subcutaneous TREMFYA